• Agriculture & Veterinary Medicine
    • A Natural Source Red Pigment

      A Natural Source Red Pigment

      A natural source red pigment with strong and stable color. The pigment appears unique and suitable for food and cosmetic industry use.

    Agriculture & Veterinary Medicine

  • Energy, Cleantech & Environmental

    Energy, Cleantech & Environmental

  • Engineering & Physical Sciences

    Engineering & Physical Sciences

  • Laboratory Research Tools & Reagents
    • Antibodies
      • CDF-4 Anti-Golgin Antibodies

        CDF-4 Anti-Golgin Antibodies

        The Golgi complex is composed of a stack of membrane-bound cisternae located in the cytoplasm adjacent to the nucleus.  The Golgi processes newly synthesized proteins (post-translational modification), sorts and routes them to their final destination.  At the outer surface of this complex or trans Golgi, vesicles containing modified proteins leave the Golgi.

        Researchers at the University of Calgary have developed and tested a monoclonal antibody that detects a component of the “trans” compartment of the Golgi apparatus.  This molecular biological tool can be used to detect the Golgi complex in a wide variety of cells including tissue culture cells such as HeLa cells, and HEp-2 cells, specialized cells (i.e. spermatids) and archived tissues. This antibody can be used as a reference marker in serological examination of patients diagnosed with Sjogren’s syndrome and other systemic autoimmune rheumatic diseases.  A large number of patients with anti-Golgi antibodies, particularly golgin97, have Sjogren’s syndrome.

      • EEA1 Monoclonal Antibodies

        EEA1 Monoclonal Antibodies

        Endocytosis is an important cellular process involved in many facets of cellular function, such as proliferative signaling, neuronal transmission, and the uptake of nutrients.  This process relies on the fusion of endocytic vesicles with early endosomes.  Early endosomes are responsible for sorting these events and recycling many of the plasma membrane associated receptors. The early endosomal antigen 1 (EEA1) protein, which is present on early endosomes, is involved in vesicle fusion during endocytosis.  In neurons, early endosomes are involved in recycling of neurotransmitter receptors, a necessary process in neuron to neuron signaling. Clinically, autoantibodies to EEA1 it have been detected in some patients with neurological deficits.  Moreover, autoantibodies to EEA1 were found to enhance excitatory synaptic transmission which may account, in part, for the neuropathies observed in patients with these autoantibodies.

        Researchers at the University of Calgary have developed and tested mouse monoclonal antibodies that specifically bind to the human EEA1 protein.  These antibodies can be utilized to detect the early endosomes by indirect immunofluorescence, immunohistochemistry, immunoprecipitation, and by Western blot analysis in both neuronal and non-neuronal cell types.

      • Monoclonal Antibodies Against Human MS4A4A

        Monoclonal Antibodies Against Human MS4A4A

      • Monoclonal Antibodies for Detection of GWBs

        Monoclonal Antibodies for Detection of GWBs

        GW bodies (GWBs, also known as mammalian P bodies) influence the expression and fate of mRNA, and thus the overall cellular mRNA profile. They are involved in the storage, transport and degradation of a subset of mRNA. GWBs are also linked to the RNA interference (RNAi) pathway resulting in either mRNA decay and/or translational repression.

        Researchers at the University of Calgary have developed mouse monoclonal antibodies that specifically bind the GW182 protein, a mRNA binding protein within GWBs. These antibodies can be utilized to detect the GW182 protein and GWBs by indirect immunofluorescence, immunohistochemistry, immunoprecipitation, and by Western blot analysis. These monoclonal antibodies can be used as reference markers to validate the presence of autoantibodies to GWBs in patients with motor/sensory neuropathy, Sjögren’s syndrome and systemic lupus erythematosus (SLE).

      • Monoclonal Antibodies to ING1 Isoforms

        Monoclonal Antibodies to ING1 Isoforms

        The ING genes encode a family of at least seven proteins with conserved plant homeodomain (PHD)-type zinc fingers in their C-termini. The founding member, ING1, is capable of binding to and affecting the activity of histone acetyltransferase (HAT), histone deacetylase (HDAC), and factor acetyltransferase (FAT) protein complexes. Upon UV irradiation, ING1 and ING2 bind stress induced signaling phospholipids such as phosphatidylinositol 5-monophosphate and cause cell cycle arrest.  ING1b interacts with proliferating cell nuclear antigen to promote DNA repair or induce apoptosis in cells to prevent tumorigenesis, depending upon the severity of DNA damage. ING proteins, which are down-regulated in a broad variety of cancer types, are able to restrict cell growth and proliferation, induce apoptosis, and modulate cell cycle progression, which strongly supports the notion that ING family proteins act as type II tumor suppressors.  The ING proteins regulate chromatin structure through specific binding to histones H3 and H4 via their plant homeodomains (PHDs) and recruitment of HAT & HDAC complexes to particular regions of chromatin, thus playing central roles in reading of the "histone code".

        Researchers at the University of Calgary have developed a panel of nine monoclonal antibodies (MAbs) against human and rodent ING1 proteins that specifically recognize the p33ING1b, p47ING1a and p24ING1c isoforms of ING1.

      • Monoclonal Antibody Against Human MS4A8B

        Monoclonal Antibody Against Human MS4A8B

      • Polyclonal Antibodies Against Human CD20

        Polyclonal Antibodies Against Human CD20


    • Research Tools

      Research Tools

    • Cell Lines Expressing Calcium Channel and Genetically-Encoded Calcium Indicators

      Cell Lines Expressing Calcium Channel and Genetically-Encoded Calcium Indicators

      Voltage-gated calcium channels are important conduits for the entry of Ca2+ into numerous cell types, and consequently are major therapeutic targets for several disease states linked to ion channels. Conventional electrophysiological approaches used to study ion channels present many challenges that impede novel research and drug discoveries.

    • Novel Peptide Suppress Cava28 Subnit Function to Reduce Inflammatory and Neuropathic Pain

      Novel Peptide Suppress Cava28 Subnit Function to Reduce Inflammatory and Neuropathic Pain

      The global market for pain management is more than $7 billion annually, representing a huge opportunity for products which displace the use of opioids as a first line of treatment.

    Laboratory Research Tools & Reagents

  • Life & Medical Sciences
    • Diagnostics
      • A Serum-Based Diagnostic Test to Identify Pediatric Septic Shock

        A Serum-Based Diagnostic Test to Identify Pediatric Septic Shock

        Prompt detection of septic shock in pediatric patients thereby reducing the mortality rates of patients.

      • Novel Planar Microelectrodes with Unique Morphological Structure for Enhanced Neural Recording

        Novel Planar Microelectrodes with Unique Morphological Structure for Enhanced Neural Recording

      • PCR-based Diagnostic for Detection of Lyme Disease Bacteria

        PCR-based Diagnostic for Detection of Lyme Disease Bacteria

        Lyme disease is the most common tick-borne disease in North America, and is transmitted by blacklegged ticks carrying Borrelia bacteria.  Infection by a tick takes at least 24 hours because of the time required for the bacteria to travel from the tick midgut to its salivary glands. Prompt removal and detection of ticks is the primary method for reducing infection; however, ~300,000 people are still infected with Lyme disease each year in the US alone.

        The bacteria responsible for causing Lyme disease are members of the genus Borrelia, with 12 of the 36 known Borrelia species causing Lyme disease.  Furthermore, the number of ticks infected with Borrelia bacteria is estimated to be increasing by 2.5% annually.  Routine surveillance uses PCR testing on ticks to determine if they carry Borrelia burgdorferi, which is the most common species found in North America; however, new species have been detected and a shift in strain prevalence due to climate changes and regional restrictions of tick travel is expected to continue occurring. 


    • Medical Devices
      • Integrated Neonatal Support with Placental Transfusion and Resuscitation (INSPIRE)

        Integrated Neonatal Support with Placental Transfusion and Resuscitation (INSPIRE)

        Current international guidelines for the management of infants at birth suggest that there be a delay before the umbilical cord is clamped, this may confer benefit by improving cardiovascular function and postnatal adaptation. Studies show that remaining connected to the umbilical cord for one to three minutes after birth reduces the risk of bleeding in the brain by as much as fifty per cent. The standard care for health newborns is to wait at least one minute after birth before cutting the umbilical cord.

      • Pneumothorax Drainage Device

        Pneumothorax Drainage Device

        Spontaneous pneumothorax is a significant global health problem with an estimated incidence of up to two million events per year globally. Air in the chest cavity can sometimes resolve itself but often requires a hospital admission and more importantly, lifesaving urgent medical care. In a military combat setting, about thirteen per cent of penetrating wounds to the thoracic cavity require thoracic intervention including a chest tube, contributing up to thirty per cent of combat deaths.

      • Trans-esophageal Aortic Compression Balloon

        Trans-esophageal Aortic Compression Balloon

        Massive blood loss from severe abdominal or distal limb trauma is challenging to control and necessitates surgical intervention. Current therapies rely on blood replacement products which can be difficult to obtain and may lead to complications for the patient. The trans-esophageal aortic compression balloon works to control blood loss, reducing the need to replace lost blood.

      Medical Devices

    • Therapeutics
      • Novel cyclodextrin-based excipients for drug formulations

        Novel cyclodextrin-based excipients for drug formulations

        Cyclodextrins (CDs) are cyclic oligosaccharides used for the improvement of water-solubility and bioavailability of medicinal products. At least six types are available on the market. This class of excipients can be readily tailored for use in drug formulations.

      • Novel Nucleoside-based Antiprotozoan Drugs

        Novel Nucleoside-based Antiprotozoan Drugs

        Infectious diseases caused by parasites are a serious global health problem with significant rates of morbidity and mortality. Due to the emergence of treatment-resistant strains of many pathogens, there is a clear need for novel approaches to infectious disease treatment.

      • Novel Proteins with Anti-bacterial and Anti-eukaryotic Activity

        Novel Proteins with Anti-bacterial and Anti-eukaryotic Activity

      • Therapeutic Application of AlphaB-cystallin Promotes Recovery from Peripheral Nerve Injury

        Therapeutic Application of AlphaB-cystallin Promotes Recovery from Peripheral Nerve Injury

        Damage to peripheral nerves often lead to dysfunction of hands, arms and legs because nerve fibers do not regrow completely in humans. Despite being a common injury, current treatment options rely on surgical anastomosis or nerve engraftment often leading to non-optimal outcomes. Moreover, adequate time for a surgery is often missed as surgical treatment decisions are made later after an initial diagnosis of the injury. An effective treatment option is needed for peripheral nerve injury as delayed surgical repair can result in only partial nerve regeneration.

        AlphaB-crystallin (HSPB5/CRYAB/αBC) is a small heat shock protein that enhances survival in response to stress by inhibiting protein aggregation, reducing levels of intracellular reactive oxygen species and inhibiting programmed cell death. αBC is constitutively expressed by the peripheral nervous system (PNS) axons and Schwann cells. The inventors discovered that loss of the crystallin impaired conduction velocity as well as motor and sensory functions were likely related to deficits in remyelination. Intravenous injections of recombinant human αBC promoted remyelination and functional recovery in wild-type mice following a sciatic nerve crush injury revealing a therapeutic effect of αBC.


    • The Mild Behavioral Impairment Checklist (MBI-C)

      The Mild Behavioral Impairment Checklist (MBI-C)

      The emergence of neuropsychiatric symptoms in older adults may provide an indicator of early neurodegenerative disease and dementia. The syndrome Mild Behavioral Impairment (MBI) describes the relationship between later-life onset of sustained neuropsychiatric symptoms and changes in behavior and personality, and the risk of cognitive decline and dementia. The International Society to Advance Alzheimer’s Research and Treatment - Alzheimer’s Association (ISTAART-AA) diagnostic criteria for MBI were published in Alzheimer's & Dementia (Ismail, et al., 2016).

    Life & Medical Sciences

  • Manufacturing & Industrial Application

    Manufacturing & Industrial Application

  • Other
    • Medical Training Devices
      • Soiled Airway Trainer

        Soiled Airway Trainer

        Approximately twenty-five per cent of pre-hospital trauma cases require airway management by emergency response personnel, and delays in proper airway management are a common cause of preventable death in pre-hospital and emergency settings. If performed improperly, airway management procedures can cause secondary injuries to patients. Training emergency personnel to effectively manage a patient's airway is vital for patient safety and optimal treatment conditions.

      Medical Training Devices

    • Womba Musical Instrument

      Womba Musical Instrument

      Empowering a child's physical and psychological development through in utero movement, artistic expression and parental bonding.


  • Social & Clinical Innovation

    Social & Clinical Innovation


Innovate Calgary is the innovation transfer and business incubator centre for the University of Calgary. As part of the Office of the Vice-President (Research) portfolio, we work closely with the Research Service Office to help bridge the gap between discovery and innovation. From ideation to commercialization, Innovate Calgary has successfully supported the innovation-driven research community for 32 years.

Our knowledge transfer and commercialization services include, but are not limited to:

  • Intellectual Property Management
  • Licensing or Company Formation
  • Technology/Innovation Marketing
  • Supporting Research Partnerships
  • Accelerator Programs



University of Calgary

The University of Calgary (UCalgary) is a publicly funded university offering more than 250 academic programs and housing more than 50 research institutes and centres. As one of Canada's top comprehensive research universities, UCalgary prepares its 30,000+ students for success in life through a high-quality educational experience made rich by research, hands-on experiences and entrepreneurial thinking. The creation and transfer of knowledge at UCalgary contributes every day to Canada's global competitive advantage and addresses society's most persistent challenges. The university has a clear strategic direction to be recognized as one of Canada's top five research universities; where research and innovative teaching go hand in hand and where it fully engages the communities it serves and leads.


  • Innovate Calgary Board of Directors

    • Dr. Edward McCauley
      Vice President (Research), University of Calgary

    • Linda Dalgetty
      Vice President, Finance & Services, University of Calgary


  • Global Access to Medicines Principles

    Global Access to Medicines Principles*

    Technologies commercialized through Innovate Calgary have the potential to advance health, protect the environment, and promote sustainability.

    In order to maximize impact, Innovate Calgary will endeavor to adhere to the following Global Access Principles:

    • To enhance the economic and societal impact of medical innovations from the University of Calgary;

    • To extend these impacts to broader global settings; and

    • To ensure fair access to these technologies for relevant communities.

    With these Global Access Principles in mind, we have identified seven strategies that will enable Innovate Calgary to adhere to this vision:

    Innovate Calgary will:

    1. Endeavor to ensure that low and middle-income countries (LMICs) have access to Innovate Calgary medical research innovations through negotiated global access terms wherever appropriate.
    2. Support access to medicines and 'health-related technologies for all' as a primary purpose of technology transfer of health-related innovation.
    3. Use commercialization models that help preserve future research and innovation.
    4. Use the Medicines Patent Pool, and similiar initiatives with a public commitment to access, where appropriate.
    5. Facilitate future innovation by patenting only when necessary to promote commercialization, utilizing non-exclusive licensing, creating streamlined processes for materials transfer and reserving broad rights to use licensed technology in future research.
    6. Promote field-of-use and jursidictional limitations in exclusive licences to improve access for those in LMICs.
    7. Support public/private partnerships to develop new technologies to benefit the resource-poor populations, including those in LMICs.


    *These principles were adapted from Universities Allied For Essential Medicines' Global Access Licensing Framework

  • Our Publications

  • Careers

    • Career Opportunities

    Innovate Calgary operates as the technology transfer and business-incubation centre for the University of Calgary. 

    Available positions:

    President & Chief Executive Officer (Full-time)

    Learn More

    Innovation Manager, Social & Clinical Sciences (Full-time)

    Learn More

    Associate Innovation Manager, Social & Clinical Sciences (Full-time, 2 yr term)

     Learn More

    Mentorship & Executive Opportunities
    Interested in supporting university-based startup or commercialization activities? Contact Us.

    Commercialization Advisor(s) - 15 Hour Engagement
    Deadline: Until suitable candidate(s) are found

    Learn More



    Volunteer Opportunities - Be a Mentor

    Venture Mentoring Services of Alberta: Licensed from the Massachusetts Institute of Technology's Venture Mentoring Service, this program was created to provide world-class mentoring to entrepreneurs throughout Alberta. 

    Learn more